Skip to main content
Journal cover image

Glycated hemoglobin measurement and prediction of cardiovascular disease.

Publication ,  Journal Article
Emerging Risk Factors Collaboration, ; Di Angelantonio, E; Gao, P; Khan, H; Butterworth, AS; Wormser, D; Kaptoge, S; Kondapally Seshasai, SR ...
Published in: JAMA
March 26, 2014

IMPORTANCE: The value of measuring levels of glycated hemoglobin (HbA1c) for the prediction of first cardiovascular events is uncertain. OBJECTIVE: To determine whether adding information on HbA1c values to conventional cardiovascular risk factors is associated with improvement in prediction of cardiovascular disease (CVD) risk. DESIGN, SETTING, AND PARTICIPANTS: Analysis of individual-participant data available from 73 prospective studies involving 294,998 participants without a known history of diabetes mellitus or CVD at the baseline assessment. MAIN OUTCOMES AND MEASURES: Measures of risk discrimination for CVD outcomes (eg, C-index) and reclassification (eg, net reclassification improvement) of participants across predicted 10-year risk categories of low (<5%), intermediate (5% to <7.5%), and high (≥ 7.5%) risk. RESULTS: During a median follow-up of 9.9 (interquartile range, 7.6-13.2) years, 20,840 incident fatal and nonfatal CVD outcomes (13,237 coronary heart disease and 7603 stroke outcomes) were recorded. In analyses adjusted for several conventional cardiovascular risk factors, there was an approximately J-shaped association between HbA1c values and CVD risk. The association between HbA1c values and CVD risk changed only slightly after adjustment for total cholesterol and triglyceride concentrations or estimated glomerular filtration rate, but this association attenuated somewhat after adjustment for concentrations of high-density lipoprotein cholesterol and C-reactive protein. The C-index for a CVD risk prediction model containing conventional cardiovascular risk factors alone was 0.7434 (95% CI, 0.7350 to 0.7517). The addition of information on HbA1c was associated with a C-index change of 0.0018 (0.0003 to 0.0033) and a net reclassification improvement of 0.42 (-0.63 to 1.48) for the categories of predicted 10-year CVD risk. The improvement provided by HbA1c assessment in prediction of CVD risk was equal to or better than estimated improvements for measurement of fasting, random, or postload plasma glucose levels. CONCLUSIONS AND RELEVANCE: In a study of individuals without known CVD or diabetes, additional assessment of HbA1c values in the context of CVD risk assessment provided little incremental benefit for prediction of CVD risk.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

JAMA

DOI

EISSN

1538-3598

Publication Date

March 26, 2014

Volume

311

Issue

12

Start / End Page

1225 / 1233

Location

United States

Related Subject Headings

  • Stroke
  • Risk Assessment
  • Prospective Studies
  • Predictive Value of Tests
  • Middle Aged
  • Male
  • Humans
  • Glycated Hemoglobin
  • General & Internal Medicine
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Emerging Risk Factors Collaboration, ., Di Angelantonio, E., Gao, P., Khan, H., Butterworth, A. S., Wormser, D., … Danesh, J. (2014). Glycated hemoglobin measurement and prediction of cardiovascular disease. JAMA, 311(12), 1225–1233. https://doi.org/10.1001/jama.2014.1873
Emerging Risk Factors Collaboration, John, Emanuele Di Angelantonio, Pei Gao, Hassan Khan, Adam S. Butterworth, David Wormser, Stephen Kaptoge, et al. “Glycated hemoglobin measurement and prediction of cardiovascular disease.JAMA 311, no. 12 (March 26, 2014): 1225–33. https://doi.org/10.1001/jama.2014.1873.
Emerging Risk Factors Collaboration, Di Angelantonio E, Gao P, Khan H, Butterworth AS, Wormser D, et al. Glycated hemoglobin measurement and prediction of cardiovascular disease. JAMA. 2014 Mar 26;311(12):1225–33.
Emerging Risk Factors Collaboration, John, et al. “Glycated hemoglobin measurement and prediction of cardiovascular disease.JAMA, vol. 311, no. 12, Mar. 2014, pp. 1225–33. Pubmed, doi:10.1001/jama.2014.1873.
Emerging Risk Factors Collaboration, Di Angelantonio E, Gao P, Khan H, Butterworth AS, Wormser D, Kaptoge S, Kondapally Seshasai SR, Thompson A, Sarwar N, Willeit P, Ridker PM, Barr ELM, Khaw K-T, Psaty BM, Brenner H, Balkau B, Dekker JM, Lawlor DA, Daimon M, Willeit J, Njølstad I, Nissinen A, Brunner EJ, Kuller LH, Price JF, Sundström J, Knuiman MW, Feskens EJM, Verschuren WMM, Wald N, Bakker SJL, Whincup PH, Ford I, Goldbourt U, Gómez-de-la-Cámara A, Gallacher J, Simons LA, Rosengren A, Sutherland SE, Björkelund C, Blazer DG, Wassertheil-Smoller S, Onat A, Marín Ibañez A, Casiglia E, Jukema JW, Simpson LM, Giampaoli S, Nordestgaard BG, Selmer R, Wennberg P, Kauhanen J, Salonen JT, Dankner R, Barrett-Connor E, Kavousi M, Gudnason V, Evans D, Wallace RB, Cushman M, D’Agostino RB, Umans JG, Kiyohara Y, Nakagawa H, Sato S, Gillum RF, Folsom AR, van der Schouw YT, Moons KG, Griffin SJ, Sattar N, Wareham NJ, Selvin E, Thompson SG, Danesh J. Glycated hemoglobin measurement and prediction of cardiovascular disease. JAMA. 2014 Mar 26;311(12):1225–1233.
Journal cover image

Published In

JAMA

DOI

EISSN

1538-3598

Publication Date

March 26, 2014

Volume

311

Issue

12

Start / End Page

1225 / 1233

Location

United States

Related Subject Headings

  • Stroke
  • Risk Assessment
  • Prospective Studies
  • Predictive Value of Tests
  • Middle Aged
  • Male
  • Humans
  • Glycated Hemoglobin
  • General & Internal Medicine
  • Female